Category: Pharmacology & Therapeutics
Keywords: Kcentra, AC Reversal, Anticoagulant (PubMed Search)
Posted: 11/6/2021 by Wesley Oliver
Click here to contact Wesley Oliver
Kcentra (four-factor prothrombin complex concentrate, 4f-PCC) is approved for the reversal of warfarin using a weight-based dosing strategy based on INR. However, since the approval of Kcentra, data has shown a fixed-dose strategy and use for direct-acting oral anticoagulants (DOAC) is appropriate. There are even recommendations to use a fixed-dose for DOACs in some situations. Utilizing a fixed-dose strategy can help with decreasing drug preparation/delivery times and costs.
Our institution now only uses a weight-based Kcentra dose of 50 units/kg for patients on DOACs with ICH or trauma-induced coagulopathy. All other patients receive a fixed-dose of Kcentra 1,500 units or 2,000 units based on anticoagulant and other criteria.
Below is a diagram summarizing our current dosing strategy for Kcentra at our institution.
DOAC=direct-acting oral anticoagulant (rivaroxaban, apixaban, and edoxaban)
Other points of interest at our institution:
Kcentra® [package insert]. CSL Behring, Marburg, Germany; 2013.
Tomaselli GF, et al. 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2020 Aug 4;76(5):594-622.
University of Maryland Medical Center. 2021. Pre- and Peri-Procedural Management of Anticoagulation, Management of Bleeding in the Setting of Anticoagulation, Intracranial Hemorrhage, and Dilutional Coagulopathies. Internal guideline.
Download the UMEM Pearls App!
Subscribe to daily UMEM Pearls (FREE!) via: